Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve ...
The production of new nurses to help address national nursing shortages starts with the educational pipeline. However, ...
YPrime, a proven leader in clinical trial technology, today announced it has received two distinctions in the 2025 Clinical ...
Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has shared an update. Medicenna Therapeutics announced a live webinar to discuss updated clinical data ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
When neurologist Steven Arnold is deciding whether to treat an Alzheimer's patient with a new therapy, he relies on averages.
UAE, Dubai: The Emirates Drug Establishment (EDE), in collaboration with the Drug Information Association (DIA), Middle East ...
UNIONDALE, NY / ACCESS Newswire / December 8, 2025 / Marquis Who’s Who, the trusted biographical authority documenting ...
BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...
In an updated report, Wave Life Sciences Ltd (NASDAQ:WVE) said that enrolled patients who took 240 mg of its drug candidate, ...
Clinical Trials Arena on MSN
Utilising real-world data to overcome challenges in rare disease research
Synthetic control arms may help tackle the unique complexities, but key challenges such as data access and standardisation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback